Lorscheider, J. Et Al. 2016. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , (London, Canada), 367-369.

Lorscheider, J., Jokubaitis, V., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., ... Horakova, D.(2016). Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis . 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) (pp.367-369). London, Canada

Lorscheider, J. Et Al. "Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis," 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 2016

Lorscheider, J. Et Al. "Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.367-369, 2016

Lorscheider, J. Et Al. (2016) . "Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.367-369.

@conferencepaper{conferencepaper, author={J. Lorscheider Et Al. }, title={Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis}, congress name={32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)}, city={London}, country={Canada}, year={2016}, pages={367-369} }